Glutathione transferase mu 2 protects glioblastoma cells against aminochrome toxicity by preventing autophagy and lysosome dysfunction

Autophagy

Volumn 10, Issue 4, 2014, Pages 618-630

  Huenchuguala, Sandro ^a   Munõz, Patricia ^a   Zavala, Patricio ^a   Villa, Mónica ^a   Cuevas, Carlos ^a   Ahumada, Ulises ^a   Graumann, Rebecca ^a   Nore, Beston F ^b,c   Couve, Eduardo ^d   Mannervik, Bengt ^e   Paris, Irmgard ^a,f   Segura Aguilar, Juan ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF SULAIMANI   (Iraq)

^d UNIVERSIDAD DE VALPARAÍSO   (Chile)

^e STOCKHOLM UNIVERSITY   (Sweden)

^f UNIVERSIDAD SANTO TOMÁS   (Chile)

Author keywords

Aminochrome; Astrocytes; Autophagy; Dopamine; Glutathione transferase; Lysosome dysfunction; Parkinson disease; siRNA

Indexed keywords

ACRIDINE ORANGE; ALPHA TUBULIN; AMINOCHROME; BAFILOMYCIN A1; CELL PROTEIN; DOPAMINE; FAT DROPLET; GLUTATHIONE TRANSFERASE M2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; NEUROTOXIN; PROTEINASE INHIBITOR; SMALL INTERFERING RNA; SQSTM1 PROTEIN; TREHALOSE; UNCLASSIFIED DRUG; AMINOCHROME 1; GLUTATHIONE S-TRANSFERASE MU 2; GLUTATHIONE TRANSFERASE; INDOLE DERIVATIVE; PROTECTIVE AGENT;

ACIDITY; ARTICLE; ASTROCYTE; ASTROCYTOMA CELL; AUTOPHAGOSOME; AUTOPHAGY; CELL DEATH; CELL PH; CELL VACUOLE; CONTROLLED STUDY; DOPAMINE UPTAKE; ELECTRON MICROSCOPY; ENZYME ACTIVITY; FLUORESCENCE ANALYSIS; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LYSOSOME; NEUROPROTECTION; NEUROTOXICITY; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; CELL LINE; METABOLISM; MITOCHONDRION; PHYSIOLOGY; TOXICITY;

ASTROCYTES; AUTOPHAGY; CELL LINE; GLIOBLASTOMA; GLUTATHIONE TRANSFERASE; HUMANS; INDOLEQUINONES; LYSOSOMES; MITOCHONDRIA; PROTECTIVE AGENTS;

EID: 84898638399     PISSN: 15548627     EISSN: 15548635     Source Type: Journal    
DOI: 10.4161/auto.27720     Document Type: Article

References (84)

1. Takeda H, Inazu M, Matsumiya T. Astroglial dopamine transport is mediated by norepinephrine transporter. Naunyn Schmiedebergs Arch Pharmacol 2002; 366:620-3; PMID:12444505; http://dx.doi.org/10.1007/s00210-002-0640-0
2. Linert W, Herlinger E, Jameson RF, Kienzl E, Jellinger K, Youdim MB. Dopamine, 6-hydroxydopamine, iron, and dioxygen - their mutual interactions and possible implication in the development of Parkinson's disease. Biochim Biophys Acta 1996; 1316:160-8; PMID:8781534; http://dx.doi.org/10.1016/0925-4439(96) 00020-8
3. Zecca L, Fariello R, Riederer P, Sulzer D, Gatti A, Tampellini D. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett 2002; 510:216-20; PMID:11801257; http://dx.doi.org/10.1016/S0014-5793(01)03269-0
4. Zecca L, Casella L, Albertini A, Bellei C, Zucca FA, Engelen M, Zadlo A, Szewczyk G, Zareba M, Sarna T. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. J Neurochem 2008; 106:1866-75; PMID:18624918
5. Norris EH, Giasson BI, Hodara R, Xu S, Trojanowski JQ, Ischiropoulos H, Lee VM. Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J Biol Chem 2005; 280:21212-9; PMID:15817478; http://dx.doi.org/10.1074/jbc.M412621200
6. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science 2001; 294:1346-9; PMID:11701929; http://dx.doi.org/10.1126/science. 1063522
7. LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG, Selkoe DJ. Dopamine covalently modifies and functionally inactivates parkin. Nat Med 2005; 11:1214-21; PMID:16227987; http://dx.doi.org/10.1038/nm1314
8. Van Laar VS, Mishizen AJ, Cascio M, Hastings TG. Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol Dis 2009; 34:487-500; PMID:19332121; http://dx.doi.org/10.1016/j.nbd.2009.03.004
9. Paris I, Perez-Pastene C, Cardenas S, Iturriaga-Vasquez P, Muñoz P, Couve E, Caviedes P, Segura-Aguilar J. Aminochrome induces disruption of actin, alpha-, and beta-tubulin cytoskeleton networks in substantia-nigra-derived cell line. Neurotox Res 2010; 18:82-92; PMID:20087799; http://dx.doi.org/10.1007/ s12640-009-9148-4
10. Baez S, Linderson Y, Segura-Aguilar J. Superoxide dismutase and catalase enhance autoxidation during one-electron reduction of aminochrome by NADPHcytochrome P-450 reductase. Biochem Mol Med 1995; 54:12-8; PMID:7551811; http://dx.doi.org/10.1006/bmme.1995.1002
11. Segura-Aguilar J, Metodiewa D, Welch CJ. Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects. Biochim Biophys Acta 1998; 1381:1-6; PMID:9659366; http://dx.doi.org/10.1016/S0304-4165(98)00036-1
12. Paris I, Dagnino-Subiabre A, Marcelain K, Bennett LB, Caviedes P, Caviedes R, Azar CO, Segura-Aguilar J. Copper neurotoxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neuronal cell line. J Neurochem 2001; 77:519-29; PMID:11299314; http://dx.doi.org/10.1046/j.1471-4159.2001.00243.x
13. Paris I, Perez-Pastene C, Martinez-Alvarado P, Graumann R, Fuentes P, Lozano J, et al. On the mechanism of dopamine-dependent copper toxicity. Neurotox Res 2005; 8:330
14. Paris I, Perez-Pastene C, Martinez-Alvarado P, Graumann R, Fuentes P, Lozano J, et al. DT-Diaphorase, monoaminergic transporter inhibitors and norepinephine prevent dopamine-dependent iron toxicity in cells derived from the Substantia nigra. Neurotox Res 2005; 8:335
15. Paris I, Martinez-Alvarado P, Cárdenas S, Perez-Pastene C, Graumann R, Fuentes P, Olea-Azar C, Caviedes P, Segura-Aguilar J. Dopamine-dependent iron toxicity in cells derived from rat hypothalamus. Chem Res Toxicol 2005; 18:415-9; PMID:15777081; http://dx.doi.org/10.1021/tx0497144
16. Paris I, Cardenas S, Lozano J, Perez-Pastene C, Graumann R, Riveros A, Caviedes P, Segura-Aguilar J. Aminochrome as a preclinical experimental model to study degeneration of dopaminergic neurons in Parkinson's disease. Neurotox Res 2007; 12:125-34; PMID:17967736; http://dx.doi.org/10.1007/BF03033921
17. Paris I, Perez-Pastene C, Couve E, Caviedes P, Ledoux S, Segura-Aguilar J. Copper dopamine complex induces mitochondrial autophagy preceding caspase-independent apoptotic cell death. J Biol Chem 2009; 284:13306-15; PMID:19265190; http://dx.doi.org/10.1074/jbc.M900323200
18. Paris I, Muñoz P, Huenchuguala S, Couve E, Sanders LH, Greenamyre JT, Caviedes P, Segura-Aguilar J. Autophagy protects against aminochrome-induced cell death in substantia nigra-derived cell line. Toxicol Sci 2011; 121:376-88; PMID:21427056; http://dx.doi.org/10.1093/toxsci/kfr060
19. Arriagada C, Paris I, Sanchez de las Matas MJ, Martinez-Alvarado P, Cardenas S, Castañeda P, Graumann R, Perez-Pastene C, Olea-Azar C, Couve E, et al. On the neurotoxicity mechanism of leukoaminochrome o-semiquinone radical derived from dopamine oxidation: mitochondria damage, necrosis, and hydroxyl radical formation. Neurobiol Dis 2004; 16:468-77; PMID:15193303; http://dx.doi.org/10.1016/j.nbd.2004.03.014
20. Fuentes P, Paris I, Nassif M, Caviedes P, Segura-Aguilar J. Inhibition of VMAT-2 and DT-diaphorase induce cell death in a substantia nigra-derived cell line - an experimental cell model for dopamine toxicity studies. Chem Res Toxicol 2007; 20:776-83; PMID:17425337; http://dx.doi.org/10.1021/tx600325u
21. Segura-Aguilar J, Lind C. On the mechanism of the Mn3(+)-induced neurotoxicity of dopamine:prevention of quinone-derived oxygen toxicity by DT diaphorase and superoxide dismutase. Chem Biol Interact 1989; 72:309-24; PMID:2557982; http://dx.doi.org/10.1016/0009-2797(89)90006-9
22. Segura-Aguilar J, Cardenas S, Riveros A, Fuentes-Bravo P, Lozano J, Graumann R, Paris I, Nassif M and Caviedes P. DT-diaphorase prevents the formation of alpha-synuclein adducts with aminochrome. Soc Neurosci Abstr 2006; 824:17
23. Cardenas SP, Perez-Pastene C, Couve E, Segura-Aguilar J. The DT-diaphorase prevents the aggregation of a-synuclein induced by aminochrome. Neurotox Res 2008; 13:136
24. Segura-Aguilar J, Baez S, Widersten M, Welch CJ, Mannervik B. Human class Mu glutathione transferases, in particular isoenzyme M2-2, catalyze detoxication of the dopamine metabolite aminochrome. J Biol Chem 1997; 272:5727-31; PMID:9038184; http://dx.doi.org/10.1074/jbc.272.9.5727
25. Baez S, Segura-Aguilar J, Widersten M, Johansson AS, Mannervik B. Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem J 1997; 324:25-8; PMID:9164836
26. Xie R, Nguyen S, McKeehan WL, Liu L. Acetylated microtubules are required for fusion of autophagosomes with lysosomes. BMC Cell Biol 2010; 11:89; PMID:21092184; http://dx.doi.org/10.1186/1471-2121-11-89
27. Dagnino-Subiabre A, Cassels BK, Baez S, Johansson AS, Mannervik B, Segura-Aguilar J. Glutathione transferase M2-2 catalyzes conjugation of dopamine and dopa o-quinones. Biochem Biophys Res Commun 2000; 274:32-6; PMID:10903891; http://dx.doi.org/10.1006/bbrc.2000.3087
28. Cheng FC, Kuo JS, Chia LG, Dryhurst G. Elevated 5-S-cysteinyldopamine/ homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease. J Neural Transm 1996; 103:433-46; PMID:9617787; http://dx.doi.org/10.1007/BF01276419
29. Rosengren E, Linder-Eliasson E, Carlsson A. Detection of 5-S-cysteinyldopamine in human brain. J Neural Transm 1985; 63:247-53; PMID:3840838; http://dx.doi.org/10.1007/BF01252029
30. Carstam R, Brinck C, Hindemith-Augustsson A, Rorsman H, Rosengren E. The neuromelanin of the human substantia nigra. Biochim Biophys Acta 1991; 1097:152-60; PMID:1911888; http://dx.doi.org/10.1016/0925-4439(91)90100-N
31. Yoshimori T, Yamamoto A, Moriyama Y, Futai M, Tashiro Y. Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase, inhibits acidification and protein degradation in lysosomes of cultured cells. J Biol Chem 1991; 266:17707-12; PMID:1832676
32. Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R, Tashiro Y. Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells. Cell Struct Funct 1998; 23:33-42; PMID:9639028; http://dx.doi.org/10.1247/csf. 23.33
33. Sarkar S, Davies JE, Huang Z, Tunnacliffe A, Rubinsztein DC. Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein. J Biol Chem 2007; 282:5641-52; PMID:17182613; http://dx.doi.org/10.1074/jbc.M609532200
34. Takeuchi H, Kondo Y, Fujiwara K, Kanzawa T, Aoki H, Mills GB, Kondo S. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res 2005; 65:3336-46; PMID:15833867
35. Boya P, Andreau K, Poncet D, Zamzami N, Perfettini J-L, Metivier D, Ojcius DM, Jäättelä M, Kroemer G. Lysosomal membrane permeabilization induces cell death in a mitochondrion-dependent fashion. J Exp Med 2003; 197:1323-34; PMID:12756268; http://dx.doi.org/10.1084/jem.20021952
36. Pivtoraiko VN, Harrington AJ, Mader BJ, Luker AM, Caldwell GA, Caldwell KA, Roth KA, Shacka JJ. Low-dose bafilomycin attenuates neuronal cell death associated with autophagy-lysosome pathway dysfunction. J Neurochem 2010; 114:1193-204; PMID:20534000
37. Shacka JJ, Klocke BJ, Shibata M, Uchiyama Y, Datta G, Schmidt RE, Roth KA. Bafilomycin A1 inhibits chloroquine-induced death of cerebellar granule neurons. Mol Pharmacol 2006; 69:1125-36; PMID:16391239; http://dx.doi.org/10. 1124/mol.105.018408
38. Traganos F, Darzynkiewicz Z. Lysosomal proton pump activity: supravital cell staining with acridine orange differentiates leukocyte subpopulations. Methods Cell Biol 1994; 41:185-94; PMID:7532261; http://dx.doi.org/10.1016/ S0091-679X(08)61717-3
39. Bednarski E, Lynch G. Cytosolic proteolysis of tau by cathepsin D in hippocampus following suppression of cathepsins B and L. J Neurochem 1996; 67:1846-55; PMID:8863489; http://dx.doi.org/10.1046/j.1471-4159.1996.67051846.x
40. Guha S, Padh H. Cathepsins: fundamental effectors of endolysosomal proteolysis. Indian J Biochem Biophys 2008; 45:75-90; PMID:21086720
41. Komatsu M, Ichimura Y. Physiological significance of selective degradation of p62 by autophagy. FEBS Lett 2010; 584:1374-8; PMID:20153326; http://dx.doi.org/10.1016/j.febslet.2010.02.017
42. Schousboe A, Bak LK, Sickmann HM, Sonnewald U, Waagepetersen HS. Energy substrates to support glutamatergic and GABAergic synaptic function: role of glycogen, glucose and lactate. Neurotox Res 2007; 12:263-8; PMID:18201953; http://dx.doi.org/10.1007/BF03033909
43. Pellerin L, Bouzier-Sore AK, Aubert A, Serres S, Merle M, Costalat R, Magistretti PJ. Activity-dependent regulation of energy metabolism by astrocytes: an update. Glia 2007; 55:1251-62; PMID:17659524; http://dx.doi.org/10.1002/glia.20528
44. Pellerin L. Brain energetics (thought needs food). Curr Opin Clin Nutr Metab Care 2008; 11:701-5; PMID:18971641; http://dx.doi.org/10.1097/MCO. 0b013e328312c368
45. Nehlig A, Coles JA. Cellular pathways of energy metabolism in the brain: is glucose used by neurons or astrocytes? Glia 2007; 55:1238-50; PMID:17659529; http://dx.doi.org/10.1002/glia.20376
46. McKenna MC. The glutamate-glutamine cycle is not stoichiometric: fates of glutamate in brain. J Neurosci Res 2007; 85:3347-58; PMID:17847118; http://dx.doi.org/10.1002/jnr.21444
47. Yang CZ, Zhao R, Dong Y, Chen XQ, Yu AC. Astrocyte and neuron intone through glutamate. Neurochem Res 2008; 33:2480-6; PMID:18563562; http://dx.doi.org/10.1007/s11064-008-9758-x
48. Banerjee R, Vitvitsky V, Garg SK. The undertow of sulfur metabolism on glutamatergic neurotransmission. Trends Biochem Sci 2008; 33:413-9; PMID:18703339; http://dx.doi.org/10.1016/j.tibs.2008.06.006
49. Dringen R, Hirrlinger J. Glutathione pathways in the brain. Biol Chem 2003; 384:505-16; PMID:12751781; http://dx.doi.org/10.1515/BC.2003.059
50. Hirrlinger J, Dringen R. The cytosolic redox state of astrocytes: Maintenance, regulation and functional implications for metabolite trafficking. Brain Res Rev 2010; 63:177-88; PMID:19883686; http://dx.doi.org/10.1016/j. brainresrev.2009.10.003
51. Croisier E, Graeber MB. Glial degeneration and reactive gliosis in alpha-synucleinopathies: the emerging concept of primary gliodegeneration. Acta Neuropathol 2006; 112:517-30; PMID:16896905; http://dx.doi.org/10.1007/s00401- 006-0119-z
52. Ishida Y, Nagai A, Kobayashi S, Kim SU. Upregulation of protease-activated receptor-1 in astrocytes in Parkinson disease: astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase. J Neuropathol Exp Neurol 2006; 65:66-77; PMID:16410750; http://dx.doi.org/10.1097/01.jnen.0000195941.48033.eb
53. Ericson C, Georgievska B, Lundberg C. Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease. Eur J Neurosci 2005; 22:2755-64; PMID:16324109; http://dx.doi.org/10.1111/j.1460-9568.2005.04503.x
54. Safi R, Gardaneh M, Panahi Y, Maghsoudi N, Zaefizadeh M, Gharib E. Optimized quantities of GDNF overexpressed by engineered astrocytes are critical for protection of neuroblastoma cells against 6-OHDA toxicity. J Mol Neurosci 2012; 46:654-65; PMID:21969113; http://dx.doi.org/10.1007/s12031-011-9654-8
55. Gardaneh M, Gholami M, Maghsoudi N. Synergy between glutathione peroxidase-1 and astrocytic growth factors suppresses free radical generation and protects dopaminergic neurons against 6-hydroxydopamine. Rejuvenation Res 2011; 14:195-204; PMID:21222532; http://dx.doi.org/10.1089/rej.2010.1080
56. Kato H, Kurosaki R, Oki C, Araki T. Arundic acid, an astrocyte-modulating agent, protects dopaminergic neurons against MPTP neurotoxicity in mice. Brain Res 2004; 1030:66-73; PMID:15567338; http://dx.doi.org/10.1016/j.brainres.2004. 09.046
57. Gan L, Vargas MR, Johnson DA, Johnson JA. Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model. J Neurosci 2012; 32:17775-87; PMID:23223297; http://dx.doi.org/10.1523/JNEUROSCI.3049-12. 2012
58. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997; 236:313-22; PMID:9240432; http://dx.doi.org/10.1006/bbrc.1997.6943
59. Perego C, Vanoni C, Massari S, Raimondi A, Pola S, Cattaneo MG, Francolini M, Vicentini LM, Pietrini G. Invasive behaviour of glioblastoma cell lines is associated with altered organisation of the cadherin-catenin adhesion system. J Cell Sci 2002; 115:3331-40; PMID:12140264
60. Chuang JI, Chen TH. Effect of melatonin on temporal changes of reactive oxygen species and glutathione after MPP(+) treatment in human astrocytoma U373MG cells. J Pineal Res 2004; 36:117-25; PMID:14962063; http://dx.doi.org/10. 1046/j.1600-079X.2003.00107.x
61. Hayer-Zillgen M, Brüss M, Bönisch H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol 2002; 136:829-36; PMID:12110607; http://dx.doi.org/10. 1038/sj.bjp.0704785
62. Díaz-Véliz G, Mora S, Gómez P, Dossi MT, Montiel J, Arriagada C, Aboitiz F, Segura-Aguilar J. Behavioral effects of manganese injected in the rat substantia nigra are potentiated by dicumarol, a DT-diaphorase inhibitor. Pharmacol Biochem Behav 2004; 77:245-51; PMID:14751451; http://dx.doi.org/10.1016/j.pbb.2003.10.016
63. Shen XM, Xia B, Wrona MZ, Dryhurst G. Synthesis, redox properties, in vivo formation, and neurobehavioral effects of N-acetylcysteinyl conjugates of dopamine: possible metabolites of relevance to Parkinson's disease. Chem Res Toxicol 1996; 9:1117-26; PMID:8902266; http://dx.doi.org/10.1021/tx960052v
64. Webb JL, Ravikumar B, Rubinsztein DC. Microtubule disruption inhibits autophagosome-lysosome fusion: implications for studying the roles of aggresomes in polyglutamine diseases. Int J Biochem Cell Biol 2004; 36:2541-50; PMID:15325591; http://dx.doi.org/10.1016/j.biocel.2004.02.003
65. Boya P, Gonzalez-Polo RA, Poncet D, Andreau K, Vieira HL, Roumier T, Perfettini JL, Kroemer G. Mitochondrial membrane permeabilization is a critical step of lysosome-initiated apoptosis induced by hydroxychloroquine. Oncogene 2003; 22:3927-36; PMID:12813466; http://dx.doi.org/10.1038/sj.onc.1206622
66. Usenovic M, Tresse E, Mazzulli JR, Taylor JP, Krainc D. Deficiency of ATP13A2 leads to lysosomal dysfunction, α-synuclein accumulation, and neurotoxicity. J Neurosci 2012; 32:4240-6; PMID:22442086; http://dx.doi.org/10. 1523/JNEUROSCI.5575-11.2012
67. Dehay B, Ramirez A, Martinez-Vicente M, Perier C, Canron M-H, Doudnikoff E, Vital A, Vila M, Klein C, Bezard E. Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc Natl Acad Sci U S A 2012; 109:9611-6; PMID:22647602; http://dx.doi.org/10.1073/pnas.1112368109
68. Chu CT. Autophagic stress in neuronal injury and disease. J Neuropathol Exp Neurol 2006; 65:423-32; PMID:16772866; http://dx.doi.org/10.1097/01.jnen. 0000229233.75253.be
69. Fass E, Shvets E, Degani I, Hirschberg K, Elazar Z. Microtubules support production of starvation-induced autophagosomes but not their targeting and fusion with lysosomes. J Biol Chem 2006; 281:36303-16; PMID:16963441; http://dx.doi.org/10.1074/jbc.M607031200
70. Köchl R, Hu XW, Chan EY, Tooze SA. Microtubules facilitate autophagosome formation and fusion of autophagosomes with endosomes. Traffic 2006; 7:129-45; PMID:16420522; http://dx.doi.org/10.1111/j.1600-0854.2005.00368. x
71. Mackeh R, Perdiz D, Lorin S, Codogno P, Poüs C. Autophagy and microtubules - new story, old players. J Cell Sci 2013; 126:1071-80; PMID:23620510; http://dx.doi.org/10.1242/jcs.115626
72. Fan X, Luo G, Yang D, Ming M, Liu H, Pu P, Le W. Critical role of lysosome and its associated protein cathepsin D in manganese-induced toxicity in cultured midbrain astrocyte. Neurochem Int 2010; 56:291-300; PMID:19913584; http://dx.doi.org/10.1016/j.neuint.2009.11.001
73. Banay-Schwartz M, Dahl D, Hui KS, Lajtha A. The breakdown of the individual neurofilament proteins by cathepsin D. Neurochem Res 1987; 12:361-7; PMID:3600962; http://dx.doi.org/10.1007/BF00993246
74. Sevlever D, Jiang P, Yen S-HC. Cathepsin D is the main lysosomal enzyme involved in the degradation of α-synuclein and generation of its carboxy-terminally truncated species. Biochemistry 2008; 47:9678-87; PMID:18702517; http://dx.doi.org/10.1021/bi800699v
75. Terland O, Flatmark T, Tangerås A, Grønberg M. Dopamine oxidation generates an oxidative stress mediated by dopamine semiquinone and unrelated to reactive oxygen species. J Mol Cell Cardiol 1997; 29:1731-8; PMID:9220358; http://dx.doi.org/10.1006/jmcc.1997.0412
76. Terland O, Almås B, Flatmark T, Andersson KK, Sørlie M. One-electron oxidation of catecholamines generates free radicals with an in vitro toxicity correlating with their lifetime. Free Radic Biol Med 2006; 41:1266-71; PMID:17015173; http://dx.doi.org/10.1016/j.freeradbiomed.2006.07.009
77. Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, Tanaka K, Cuervo AM, Czaja MJ. Autophagy regulates lipid metabolism. Nature 2009; 458:1131-5; PMID:19339967; http://dx.doi.org/10.1038/nature07976
78. Zafar KS, Siegel D, Ross D. A potential role for cyclized quinones derived from dopamine, DOPA, and 3,4-dihydroxyphenylacetic acid in proteasomal inhibition. Mol Pharmacol 2006; 70:1079-86; PMID:16790533; http://dx.doi.org/10. 1124/mol.106.024703
79. Martinez-Vicente M, Talloczy Z, Kaushik S, Massey AC, Mazzulli J, Mosharov EV, Hodara R, Fredenburg R, Wu DC, Follenzi A, et al. Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest 2008; 118:777-88; PMID:18172548
80. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411:494-8; PMID:11373684; http://dx.doi.org/10.1038/35078107
81. Harborth J, Elbashir SM, Bechert K, Tuschl T, Weber K. Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci 2001; 114:4557-65; PMID:11792820
82. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001; 15:188-200; PMID:11157775; http://dx.doi.org/10.1101/gad.862301
83. Heinonen JE, Smith CI, Nore BF. Silencing of Bruton's tyrosine kinase (Btk) using short interfering RNA duplexes (siRNA). FEBS Lett 2002; 527:274-8; PMID:12220673; http://dx.doi.org/10.1016/S0014-5793(02)03206-4
84. Hetz C, Thielen P, Matus S, Nassif M, Court F, Kiffin R, Martinez G, Cuervo AM, Brown RH, Glimcher LH. XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. Genes Dev 2009; 23:2294-306; PMID:19762508; http://dx.doi.org/10.1101/gad.1830709